Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS)

被引:52
|
作者
El Hajj, Albert [1 ]
Ploussard, Guillaume [1 ]
de la Taille, Alexandre [1 ]
Allory, Yves [2 ]
Vordos, Dimitri [1 ]
Hoznek, Andras [1 ]
Abbou, Claude Clement [1 ]
Salomon, Laurent [1 ]
机构
[1] CHU Henri Mondor, APHP, Dept Urol, F-94010 Creteil, France
[2] CHU Henri Mondor, APHP, Dept Pathol, F-94010 Creteil, France
关键词
active surveillance; low risk; prostate cancer; radical prostatectomy; biopsy; CANCER PATIENTS; PATHOLOGICAL OUTCOMES; STRINGENT CRITERIA; EPSTEIN CRITERIA; REPEAT BIOPSY; RISK; MEN; VALIDATION; CANDIDATES; EXPERIENCE;
D O I
10.1111/j.1464-410X.2012.11276.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To identify the risk of failure of active surveillance (AS) in men who had the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria and had undergone radical prostatectomy (RP), by studying as primary endpoints the risk of unfavourable disease in RP specimens (stage >T2 and/or Gleason score >6) and of biochemical progression after RP. Patients and Methods We assessed 626 patients who had the PRIAS criteria for AS defined as T1c/T2, PSA level of <= 10 ng/mL, PSA density (PSAD) of <0.2 ng/mL per mL, Gleason score of <7, and one or two positive biopsies. All patients underwent immediate RP at our department between January 1991 and December 2010. Multivariate logistic regression was used to test factors correlated with the risk of unfavourable prostate cancer. The risk of progression was tested using multivariate Cox regression models. Biochemical recurrence-free survival (BFS) was established using the Kaplan-Meier method Results Pathological study of RP specimens showed upstaging (>T2) in 129 patients (20.6%), upgrading (Gleason score >6) in 281 (44.9%) and unfavourable disease in 312 patients (50%). There was a statistically non-significant trend for BFS at P = 0.06. Predictors of favourable tumours were age <65 years (P = 0.005), one vs two positive biopsies (P = 0.01) and a biopsy core number >12 (P = 0.005). Preoperative factors predicting disease progression were a PSAD of >0.15 ng/mL(2) (P = 0.008) and biopsy core number of <= 12 (P = 0.017). Conclusions Even with stringent AS criteria, the rate of unfavourable disease remains high. Predictive factors of unfavourable disease and biochemical progression should be considered when including patients in AS protocols.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [21] PREDICTORS OF PATHOLOGICAL UPGRADING AND UPSTAGING IN PATIENTS ELIGIBLE FOR ACTIVE SURVEILLANCE SUBMITTED TO RADICAL PROSTATECTOMY
    Autran-Gomez, Ana Maria
    Secin, Fernando P.
    Sivaraman, Arjun
    Salas, Rafael Sanchez
    Monzo, Juan I.
    Prapotnich, Dominique
    Barret, Eric
    Rozet, Francois
    Galiano, Marc
    Mombet, Annick
    Cathala, Nathalia
    Cathelineau, Xavier
    JOURNAL OF UROLOGY, 2015, 193 (04): : E515 - E516
  • [22] Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study
    Tohi, Yoichiro
    Kato, Takuma
    Miyakawa, Jimpei
    Matsumoto, Ryuji
    Sasaki, Hiroshi
    Mitsuzuka, Koji
    Inokuchi, Junichi
    Matsumura, Masafumi
    Yokomizo, Akira
    Kinoshita, Hidefumi
    Hara, Isao
    Kawamura, Norihiko
    Hashimoto, Kohei
    Inoue, Masaharu
    Teishima, Jun
    Kanno, Hidenori
    Fukuhara, Hiroshi
    Maruyama, Satoru
    Sakamoto, Shinichi
    Saito, Toshihiro
    Kakehi, Yoshiyuki
    Sugimoto, Mikio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (09) : 1056 - 1061
  • [23] Predictors of pathological upgrading and upstaging in patients eligible for active surveillance submitted to radical prostatectomy (RARP).
    Autran-Gomez, Ana Maria
    Secin, Fernando P.
    Sivaraman, Arjun
    Sanchez-Salas, Rafael
    Monzo, Juan I.
    Prapotnich, Dominic
    Barret, Eric
    Rozet, Francois
    Galiano, Marc
    Mombet, Annick
    Cathala, Nathalia
    Cathelineau, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [24] Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy
    Drouin, Sarah J.
    Comperat, Eva
    Cussenot, Olivier
    Bitker, Marc-Olivier
    Haertig, Alain
    Roupret, Morgan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (04) : 402 - 407
  • [25] PATHOLOGIC FINDINGS AT RADICAL PROSTATECTOMY OF MEN ELIGIBLE FOR ACTIVE SURVEILLANCE: IMPACT OF RACE
    DeLay, Kenneth
    Williams, Michael
    Given, Robert
    Lance, Raymond
    JOURNAL OF UROLOGY, 2014, 191 (04): : E515 - E515
  • [26] Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance
    Balakrishnan, Ashwin S.
    Cowan, Janet E.
    Cooperberg, Matthew R.
    Shinohara, Katsuto
    Nguyen, Hao G.
    Carroll, Peter R.
    JOURNAL OF UROLOGY, 2019, 202 (03): : 506 - 510
  • [27] PATHOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY FOLLOWING ACTIVE SURVEILLANCE
    Satkunasivam, Raj
    Kulkarni, Girish
    Kalnin, Robin
    Trachtenberg, John
    Fleshner, Neil
    Jewett, Michael
    Zlotta, Alexandre
    Robinette, Michael
    Finelli, Antonio
    JOURNAL OF UROLOGY, 2012, 187 (04): : E207 - E207
  • [28] Pathology findings after radical prostatectomy for prostate cancer in patients eligible for active surveillance: Contribution of multiparametric MRI to treatment decision
    Martin-Malburet, A.
    Marcq, G.
    Leroy, X.
    Guiffart, P.
    Fantoni, J. -C.
    Flannand, V.
    Villers, A.
    Puech, P.
    Ouzzane, A.
    PROGRES EN UROLOGIE, 2018, 28 (8-9): : 425 - 433
  • [29] A review of radical prostatectomy outcomes in active surveillance patients-The Sunnybrook experience
    Jethava, V.
    Vesprini, D.
    Loblaw, D. A.
    Mamedov, A.
    Nam, R.
    Klotz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [30] Defining the risk of disease progression following radical prostatectomy in candidates for active surveillance using the PRIAS criteria
    El Hajj, A.
    Ploussard, G.
    Radulescu, C.
    Defourmestraux, A.
    Gillion, N.
    Vordos, D.
    Hoznek, A.
    Yiou, R.
    Allory, Y.
    De La Taille, A.
    Abbou, C. C.
    Salomon, L.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E1090 - U269